PO

SonicWall Introduces Monthly Firewall Security Services Bundles for MSSPs, MSPs

Retrieved on: 
星期三, 六月 28, 2023
Forward Commitment Procurement, ConnectWise Control, TZ, Security agency, Workflow, SonicWall, ATP, PO, RMM, MSP, Professional services automation, Organization, Member of the Scottish Parliament, Managed services, NSM, TCO, MSSP, PSA, Medical device, Food delivery, Financial services, Online shopping

MILPITAS, Calif., June 28, 2023 /PRNewswire/ -- SonicWall, a 100% channel cybersecurity leader, today announced the availability of monthly firewall security services bundles for Managed Security Service Providers (MSSPs) and approved Managed Service Providers (MSPs).

Key Points: 
  • SonicWall MSSPs and approved MSPs can simplify the purchase process by procuring critical threat protection capabilities on a monthly, no-commit basis and extend firewall hardware licensing
    MILPITAS, Calif., June 28, 2023 /PRNewswire/ -- SonicWall, a 100% channel cybersecurity leader, today announced the availability of monthly firewall security services bundles for Managed Security Service Providers (MSSPs) and approved Managed Service Providers (MSPs).
  • SonicWall MSSPs and approved MSPs can now bill customers monthly for SonicWall's popular security services included in three cost-effective protection tiers for SonicWall Generation 7 appliances: Threat Protection Security Suite, Essential Protection Security Suite and Advanced Protection Security Suite.
  • With bundled firewall security services conveniently billed monthly, MSSPs and approved MSPs never need to worry about missing a renewal from multi-year agreements.
  • When SonicWall Network Security Manager (NSM) licenses are added to firewall security services , partners can leverage additional management, reporting and analytics capabilities.

Nasdaq, Inc. Prices $4.25 Billion and €750 Million Senior Notes Offerings

Retrieved on: 
星期五, 六月 23, 2023
Attention, Communication, Dollar, Post office box, 8-K, Offerings, Telephone, Government Legal Department, BofA Securities, Nasdaq, Inc., PO, Business transaction management, Morgan Stanley, J.P. Morgan & Co., NDAQ, EDGAR, Government, Sale, Goldman Sachs, 3rd Floor, Prospectus, Acquisition, Euro, DCM, Madison Avenue, Merrill (company), D.2, Form 10-K, Hand, Legal Department (Hong Kong), Security (finance), Adenza, Nordea

Each Offering is expected to close on June 28, 2022, subject to customary closing conditions.

Key Points: 
  • Each Offering is expected to close on June 28, 2022, subject to customary closing conditions.
  • Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, BofA Securities, Inc., Citigroup Global Markets Inc., and Morgan Stanley & Co. LLC are acting as joint book-running managers for the Dollar Offering.
  • The Offerings will be made pursuant to an effective shelf registration statement, previously filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”).
  • The Company disclaims any obligation to update these forward-looking statements, except as required by law.

Bozeman Health Partners with Infor to Embed New AI Capabilities

Retrieved on: 
星期三, 六月 21, 2023
Amazon Web Services, OIG, Health, PO, Human, Negotiation, ERP, Government, DA, Organization, Patient, Risk, City, Growth, SCM, AWS, Medical device, Online shopping, Infor

NEW YORK, June 21, 2023 /PRNewswire/ -- Infor®, the industry cloud company, today announced the success Bozeman Health has seen with its healthcare-specific artificial intelligence (AI), supply chain (SCM), and analytics solutions. As a primary healthcare provider in one of the fastest-growing cities in the U.S., Bozeman Health was challenged to quickly expand its patient care and services without negatively impacting quality of care and increasing costs. By partnering with Infor, Bozeman has successfully integrated AI into key processes so that the organization has the tools to be more efficient and accurate to meet demands, and make smarter decisions for supply, vendor and warehouse management. These improvements will allow Bozeman to stay true to its mission in keeping patient care high at the lowest cost possible.

Key Points: 
  • These improvements will allow Bozeman to stay true to its mission in keeping patient care high at the lowest cost possible.
  • Bozeman Health selected Infor because of the company's deep expertise in the healthcare industry and its ability to provide a scalable, user-friendly, agile solution that could quickly help Bozeman boost efficiency and streamline processes.
  • A significant outcome of this transformation was that Bozeman Health staff was able to scale the vendor selection process with Infor Coleman AI by ranking suppliers by three industry benchmarks.
  • Additional integrated AI capabilities deployed at Bozeman Health include Infor Coleman Digital Assistant (DA), which empowers employees to find information by simply asking a question via text or voice chat such as stock location, PO status, and more.

Nasdaq, Inc. Announces Proposed Senior Notes Offerings

Retrieved on: 
星期二, 六月 20, 2023
Attention, Communication, Dollar, Goldman, Post office box, 8-K, Offerings, Telephone, Government Legal Department, BofA Securities, Nasdaq, Inc., PO, Business transaction management, Morgan Stanley, J.P. Morgan & Co., NDAQ, EDGAR, Government, Sale, 3rd Floor, Prospectus, Acquisition, Euro, DCM, Madison Avenue, Merrill (company), D.2, Form 10-K, Hand, Legal Department (Hong Kong), Security (finance), Adenza, Nordea

NEW YORK, June 20, 2023 (GLOBE NEWSWIRE) -- Nasdaq, Inc. (the “Company”) (Nasdaq: NDAQ) today announced that it plans to offer, subject to market and other conditions, U.S. dollar-denominated senior notes (the “Dollar Offering”) and euro-denominated senior notes (the “Euro Offering” and, together with the Dollar Offering, the “Offerings”).

Key Points: 
  • NEW YORK, June 20, 2023 (GLOBE NEWSWIRE) -- Nasdaq, Inc. (the “Company”) (Nasdaq: NDAQ) today announced that it plans to offer, subject to market and other conditions, U.S. dollar-denominated senior notes (the “Dollar Offering”) and euro-denominated senior notes (the “Euro Offering” and, together with the Dollar Offering, the “Offerings”).
  • The Offerings will be made pursuant to an effective shelf registration statement, previously filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”).
  • Forward-looking statements in this press release include, among other things, statements about the Offerings, the Company’s plans, objectives, expectations and intentions, the financial condition, results of operations and business of the Company and the proposed acquisition of Adenza.
  • The Company disclaims any obligation to update these forward-looking statements, except as required by law.

Endeavour Silver Announces Filing of Base Shelf Prospectus

Retrieved on: 
星期五, 六月 16, 2023
Attention, Granville Street, PO, Sale, Prospectus, Silver, Register, EDR, Suite, Form, TSX, NYSE, Registration statement, Security (finance)

VANCOUVER, British Columbia, June 16, 2023 (GLOBE NEWSWIRE) -- Endeavour Silver Corp. (“Endeavour” or the “Company”) (NYSE: EXK; TSX: EDR) announces today that it has filed a short form base shelf prospectus (the “Prospectus”) to provide the Company with the flexibility to take advantage of debt, convertible debt, equity and other financing opportunities that may arise during the 25-month effective period of the Prospectus.

Key Points: 
  • VANCOUVER, British Columbia, June 16, 2023 (GLOBE NEWSWIRE) -- Endeavour Silver Corp. (“Endeavour” or the “Company”) (NYSE: EXK; TSX: EDR) announces today that it has filed a short form base shelf prospectus (the “Prospectus”) to provide the Company with the flexibility to take advantage of debt, convertible debt, equity and other financing opportunities that may arise during the 25-month effective period of the Prospectus.
  • These filings enable offerings of common shares, warrants, subscription receipts, debt and convertible debt securities or units at any time during the period the Prospectus is effective.
  • Copies of the Registration Statement and the Prospectus contained therein can be obtained by contacting Endeavour Silver at PO Box 10328, Suite 1130-609 Granville Street, Vancouver, British Columbia V7Y 1G5, Attention: Christine West, Chief Financial Officer.
  • Copies of the Prospectus and the Registration Statement are also available at www.sedar.com and www.sec.gov, respectively.

Esker Issued U.S. Patent for Machine Learning Document Data Extraction

Retrieved on: 
星期二, 六月 6, 2023
Professional Services, Data Management, Technology, Finance, Software, Accounting, Patent, Deep learning, PO, Intelligence, POS, Customer service, Machine learning, Anomaly, Algorithm, AI, Automation, Sales, Medical device, Research

11631265 by the U.S. Patent and Trademark Office (USPTO) for Esker’s machine learning technology.

Key Points: 
  • 11631265 by the U.S. Patent and Trademark Office (USPTO) for Esker’s machine learning technology.
  • The patented technology addresses the need for accurate automated data extraction on incoming documents.
  • The data is read from a document and the AI creates rules that define what data to retrieve and in which format.
  • “When we started on the AI journey at Esker, we focused our efforts on data extraction in order to decrease manual data entry for incoming invoices and orders,” said Jean-Jacques Bérard, Vice President of Research and Development at Esker.

Candidates Approved for the 2023 IEEE Computer Society Election

Retrieved on: 
星期一, 六月 5, 2023
Undergraduate education, IEEE CS, Athabasca University, Planning committee, PO, Ballot, EDT, Board of Governors of the United States Postal Service, Computer, IEEE, University of California, Berkeley, Executive Committee, UTC, Osnabrück University, Clausthal University of Technology, Institute of Electrical and Electronics Engineers, Bangladesh Computer Society, LOS, Provincial Executive Committees of the African National Congress, Consumer electronics, Management

LOS ALAMITOS, Calif., June 5, 2023 /PRNewswire/ -- The IEEE Computer Society (IEEE CS) Board of Governors has approved the slate of candidates for the IEEE CS 2023 election: https://www.computer.org/volunteering/nomination-election/approved-candi... .

Key Points: 
  • LOS ALAMITOS, Calif., June 5, 2023 /PRNewswire/ -- The IEEE Computer Society (IEEE CS) Board of Governors has approved the slate of candidates for the IEEE CS 2023 election: https://www.computer.org/volunteering/nomination-election/approved-candi... .
  • Members in all regions can vote online at the IEEE CS election site.
  • Candidate bios and position statements will be published in the August issue of Computer magazine, which is distributed to all IEEE CS members.
  • All professional and graduate student IEEE CS members on record as of 1 June 2023 are eligible to vote in this year's IEEE CS election.

Connect Biopharma Announces Positive Long-Term Data from the Maintenance Period Through Week 48 of CN002 Phase 2 Icanbelimod Trial in Patients with Moderate-to-Severe Ulcerative Colitis

Retrieved on: 
星期四, 六月 1, 2023
Maintenance, University, University of Western Ontario, Week, Epidemiology, PO, CNTB, Inflammation, Ulcerative colitis, UC, Patient, SAN, Entrepreneurship, Lymphocyte, Safety, Biostatistics, Department of Medicine – University of Pamplona, Vaccine, Meat, Pharmaceutical industry, Birth control, Medicine, S1P1

Icanbelimod demonstrated sustained clinical remission, a regulatory relevant efficacy endpoint, through Week 48 in 80% of patients who achieved clinical remission at Week 12 of the induction period.

Key Points: 
  • Icanbelimod demonstrated sustained clinical remission, a regulatory relevant efficacy endpoint, through Week 48 in 80% of patients who achieved clinical remission at Week 12 of the induction period.
  • 80% (8/10) of patients who achieved clinical remission at the end of the induction period sustained it through Week 48.
  • Overall, 57% (12/21) of patients with clinical response at the end of the induction period achieved clinical remission at the end of the maintenance period.
  • Icanbelimod was well-tolerated and long-term safety data through Week 48 remained consistent with safety findings observed in the induction period.

J P Jenkins Ltd: iEnergizer Limited - Matched Bargain Dealing Facility

Retrieved on: 
星期六, 五月 27, 2023
St Martin's House, Telecommunications, Appointment, PO, ISIN, Saint Peter Port, Commercial, BFSI, Security (finance)

25th May 2023 – Shares in iEnergizer ( https://www.ienergizer.com ) have been admitted to trade on JP Jenkins share dealing platform.

Key Points: 
  • 25th May 2023 – Shares in iEnergizer ( https://www.ienergizer.com ) have been admitted to trade on JP Jenkins share dealing platform.
  • JP Jenkins is a liquidity venue for unlisted or unquoted assets in companies, enabling shareholders and prospective investors to buy and sell equity on a matched bargain basis.
  • JP Jenkins is a trading name of InfinitX Limited and Appointed Representative of Prosper Capital LLP (FRN453007).
  • Veronika Oswald, Commercial Director of J P Jenkins said: “We are delighted iEnergizer has chosen JP Jenkins as the new facility for trading their shares.

Updated Data from Part A of Verastem Oncology's RAMP 201 Trial Show an Objective Response Rate of 45% in Patients with Recurrent Low-Grade Serous Ovarian Cancer Treated with Avutometinib and Defactinib

Retrieved on: 
星期四, 五月 25, 2023
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, KRAS, Bevacizumab, FRCP, Verastem Oncology, MBBS, Avutometinib, Diarrhea, Xeroderma, Ovarian cancer, Safety, Survival, Cancer, PO, Woman, Royal Marsden Hospital, The Institute, FRAME, MEK, CPK, Rash, EMA, ORR, Vomiting, Peripheral edema, RAMP, Patient, Blood, Memorial Sloan Kettering Cancer Center, NHS foundation trust, MA, Nausea, Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Society, Breakthrough, Food, Fatigue, Pharmaceutical industry, Medical device, Part

In the RAMP 201 study, treatment with the combination of avutometinib and defactinib resulted in an objective response rate (ORR) of 45% (13/29) and tumor shrinkage in 86% (25/29) of evaluable patients.

Key Points: 
  • In the RAMP 201 study, treatment with the combination of avutometinib and defactinib resulted in an objective response rate (ORR) of 45% (13/29) and tumor shrinkage in 86% (25/29) of evaluable patients.
  • RAMP 201 is an international registration-directed Phase 2 study evaluating the safety and efficacy of avutometinib (VS-6766) alone and in combination with defactinib among patients with recurrent LGSOC.
  • The discontinuation rate, due to ≥ 1 adverse event, was 12% in the trial overall to date (4.9% due to elevated blood CPK).
  • These results indicate that the combination of avutometinib and defactinib shows promise as a tolerable treatment with impressive response rates for women with recurrent LGSOC.